Literature DB >> 1412112

Corticosteroids in acute severe asthma: effectiveness of low doses.

S D Bowler1, C A Mitchell, J G Armstrong.   

Abstract

BACKGROUND: Although the need for corticosteroids in acute severe asthma is well established the appropriate dose is not known.
METHODS: The response to intravenous hydrocortisone 50 mg (low dose), 100 mg (medium dose), and 500 mg (high dose), administered every six hours for 48 hours and followed by oral prednisone, was compared in patients with acute asthma in a double blind randomised study. After initial emergency treatment with bronchodilators subjects received oral theophylline or intravenous aminophylline and nebulised salbutamol four hourly. Patients were given low, medium, or high doses of intravenous hydrocortisone and then 20, 40, or 60 mg/day respectively of oral prednisone with a reducing regimen over the following 12 days. Beclomethasone dipropionate, 400 micrograms twice daily by metered dose inhaler, was also started. Peak expiratory flow (PEF), forced expiratory volume in one second (FEV1), and visual analogue dyspnoea scores (VAS) were recorded daily in hospital and PEF and VAS twice daily after discharge for a total of 12 days.
RESULTS: The 66 subjects (40 female) who completed the study had a mean (SD) age of 31(14) years. On presentation mean (SD) FEV1% predicted in the low (n = 22), medium (n = 20), and high dose (n = 24) groups was 17(13), 19(12), and 19(11) and after emergency bronchodilator treatment 32(20), 30(12), and 36(13). After 24 hours of treatment the respective post-bronchodilator FEV1% predicted values were 62(22), 62(23), and 65(28) compared with 71(24), 69(22), and 71(24) after 48 hours. No significant difference between the groups was detected. PEF and VAS improved with treatment over the 12 days but was not influenced by steroid dose.
CONCLUSIONS: Hydrocortisone 50 mg intravenously four times a day for two days followed by low dose oral prednisone is as effective in resolving acute severe asthma as 200 or 500 mg of hydrocortisone followed by higher doses of prednisone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412112      PMCID: PMC463917          DOI: 10.1136/thx.47.8.584

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  High-dose corticosteroids in severe acute asthma.

Authors:  M G Britton; J V Collins; D Brown; N P Fairhurst; R G Lambert
Journal:  Br Med J       Date:  1976-07-10

2.  Dosage and time effects of inhaled budesonide on bronchial hyperreactivity.

Authors:  J Kraan; G H Koëter; T W van der Mark; M Boorsma; J Kukler; H J Sluiter; K De Vries
Journal:  Am Rev Respir Dis       Date:  1988-01

3.  A study of cortisol metabolism in patients with chronic asthma.

Authors:  J Dwyer; L Lazarus; J B Hickie
Journal:  Australas Ann Med       Date:  1967-11

4.  The use of corticosteroids in the treatment of acute asthma.

Authors:  J V Collins; T J Clark; D Brown; J Townsend
Journal:  Q J Med       Date:  1975-04

5.  Risk factors for hydrocortisone myopathy in acute severe asthma.

Authors:  C D Shee
Journal:  Respir Med       Date:  1990-05       Impact factor: 3.415

6.  Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure.

Authors:  B D Harrison; T C Stokes; G J Hart; D A Vaughan; N J Ali; A A Robinson
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

7.  A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma.

Authors:  J H Toogood; N M Lefcoe; D S Haines; B Jennings; N Errington; L Baksh; L Chuang
Journal:  J Allergy Clin Immunol       Date:  1977-04       Impact factor: 10.793

8.  Treatment of status asthmaticus in children with high doses and conventional doses of methylprednisolone.

Authors:  H Harfi; A S Hanissian; L V Crawford
Journal:  Pediatrics       Date:  1978-06       Impact factor: 7.124

9.  A double-blind, randomized clinical trial of methylprednisolone in status asthmaticus.

Authors:  R J Haskell; B M Wong; J E Hansen
Journal:  Arch Intern Med       Date:  1983-07

10.  Glucocorticoids in acute asthma. A critical controlled trial.

Authors:  C H Fanta; T H Rossing; E R McFadden
Journal:  Am J Med       Date:  1983-05       Impact factor: 4.965

View more
  8 in total

Review 1.  Status asthmaticus. From the emergency department to the intensive care unit.

Authors:  N Kenyon; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

2.  Effects of corticosteroids in acute severe asthma.

Authors:  N C Barnes
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 3.  Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital.

Authors:  Sarah Aldington; Richard Beasley
Journal:  Thorax       Date:  2007-05       Impact factor: 9.139

Review 4.  Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society.

Authors:  R C Beveridge; A F Grunfeld; R V Hodder; P R Verbeek
Journal:  CMAJ       Date:  1996-07-01       Impact factor: 8.262

5.  Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital.

Authors:  N J Innes; J A Stocking; T J Daynes; B D W Harrison
Journal:  Thorax       Date:  2002-12       Impact factor: 9.139

Review 6.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Comparing the efficacy and safety of two regimens of sequential systemic corticosteroids in the treatment of acute exacerbation of bronchial asthma.

Authors:  Praveen Aggarwal; Sanjeev Bhoi
Journal:  J Emerg Trauma Shock       Date:  2010-07

Review 8.  An umbrella review: corticosteroid therapy for adults with acute asthma.

Authors:  Jerry A Krishnan; Steven Q Davis; Edward T Naureckas; Peter Gibson; Brian H Rowe
Journal:  Am J Med       Date:  2009-11       Impact factor: 4.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.